London, 25th April
Biosimilar medicines are an essential part of healthcare provision in Europe today. Europe will continue to play a leading role in shaping a sustainable regulatory framework regionally and globally to promote greater access to essential therapies for auto-immune diseases and cancer. The Biosimilar Medicines Group has pioneered this development and supports greater global cooperation for future development.
It was a great opportunity: WFIP was one of the five invited patient advocacy organizations and was asked to wrap up and close the conference with closing remarks.
Here you can read the final report.